Therapeutics
References 1 Jespersen, H et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat. Commun. 8, (2017). 21 Hanazawa, A et al. Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. Front. Immunol. 9, (2018). 3Takahashi, T et al. Enhanced Antibody Responses in a Novel NOG Transgenic Mouse with Restored Lymph Node Organogenesis. Front. Immunol. 8, (2018). 4 Ito, R et al. Establishment of a Human Allergy Model Using Human IL-3/GM-CSF- Transgenic NOG Mice. J. Immunol. 191, 2890–2899 (2013). 5 Katano, I et al. Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci. Rep. 7, 17230 (2017).
innovative cell therapies are developed, the test systems sufficient to support them must improve in order to complement their unique biological requirements. Whether CAR-T, dendritic cell or natural killer
cells become the standards for cancer treatment will be critically dependent on whether in vivo test systems fully translate their potential into the human clinical setting. Creative solutions to com- plement the evolutionary distance between mouse and humans has provided transgenic cytokine- expressing immune-deficient mice. This is good, but the work does not stop there. Future develop- ments are aimed at fully developing the most vali- dated complementary system to replicate the clini- cal setting. Further work, designed to both engi- neer a better host and build better cell and tissue humanisation practices, are currently under devel- opment. With better elucidation of the basic requirements for human tumour and immune cell recapitulation, model systems can concomitantly evolve to meet the changing landscape of cell ther- apy testing.
DDW
Dr Azusa Tanaka is product manager at Taconic Biosciences. Dr Tanaka has a PhD in immunology from the University of Chicago. She has published in multiple
journals,
including Nature
Immunology, and was interviewed for a USA Today article regarding immunology, cell and gene therapies and immuno-oncology.
Dr Michael Seiler is vice-president, commercial products at Taconic Biosciences. Dr Seiler has a PhD in interdisciplinary cell and molecular biology from the Baylor College of Medicine and complet- ed postdoctoral research in immune cell develop- ment at the University of Chicago. Dr Seiler has authored 15 articles on gene and cell therapies and immune cell developmental biology.
Advanced Cell Diagnostics Agilent Technologies, Inc Biostrata Ltd
BioTek Instruments, Inc BMG Labtech GmbH
Charles River Laboratories, Inc
13
30,54 65 16
38,60 24,53
ADVERTISEMENT INDEX 41
Chemspec Europe
IntelliCyt Corporation Labcyte, Inc Mitra Biotech PerkinElmer, Inc
Quanterix Corporation
3 6
22-23 OBC IFC
Select Biosciences Ltd Source Bioscience
Taconic Biosciences, Inc Takara Bio USA, Inc
IBC 4
63 37
70
Drug Discovery World Spring 2018
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
